• Je něco špatně v tomto záznamu ?

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma

MA. Gouda, J. Polivka, HJ. Huang, I. Treskova, K. Pivovarcikova, T. Fikrle, V. Woznica, DJ. Dustin, SG. Call, F. Meric-Bernstam, M. Pesta, F. Janku

. 2022 ; 7 (1) : 100357. [pub] 20211220

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011134

Grantová podpora
P30 CA016672 NCI NIH HHS - United States
UL1 TR000371 NCATS NIH HHS - United States

BACKGROUND: Implementation of adjuvant therapies in non-metastatic melanoma improved treatment outcomes in some patients; however, adjuvant therapy can be associated with significant cost and risk of toxicity. Therefore, there is an unmet need to better identify patients at high risk of recurrence. PATIENTS AND METHODS: We carried out an ultrasensitive droplet digital PCR (ddPCR)-based detection of BRAFV600E-mutated circulating tumor DNA (ctDNA) from blood samples prospectively collected before surgery, 1 hour after surgery, and then serially during follow-up. RESULTS: In 80 patients (stages ≤III), BRAFV600E mutations were detected in 47.2% of tissue, in 37.7% of ctDNA samples collected before surgery, and in 25.9% of ctDNA samples collected 1 hour after surgery. Patients with detected ctDNA in blood collected 1 hour after surgery compared to patients without detected ctDNA had higher likelihood of melanoma recurrence (P < 0.001) and shorter median disease-free survival (P = 0.001) and overall survival (P = 0.003). CONCLUSIONS: Ultrasensitive ddPCR can detect ctDNA in pre- and post-surgical blood samples from patients with resectable melanoma. Detection of ctDNA in post-surgical samples is associated with inferior treatment outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011134
003      
CZ-PrNML
005      
20230310090106.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.esmoop.2021.100357 $2 doi
035    __
$a (PubMed)34942440
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Gouda, M A $u Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
245    10
$a Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma / $c MA. Gouda, J. Polivka, HJ. Huang, I. Treskova, K. Pivovarcikova, T. Fikrle, V. Woznica, DJ. Dustin, SG. Call, F. Meric-Bernstam, M. Pesta, F. Janku
520    9_
$a BACKGROUND: Implementation of adjuvant therapies in non-metastatic melanoma improved treatment outcomes in some patients; however, adjuvant therapy can be associated with significant cost and risk of toxicity. Therefore, there is an unmet need to better identify patients at high risk of recurrence. PATIENTS AND METHODS: We carried out an ultrasensitive droplet digital PCR (ddPCR)-based detection of BRAFV600E-mutated circulating tumor DNA (ctDNA) from blood samples prospectively collected before surgery, 1 hour after surgery, and then serially during follow-up. RESULTS: In 80 patients (stages ≤III), BRAFV600E mutations were detected in 47.2% of tissue, in 37.7% of ctDNA samples collected before surgery, and in 25.9% of ctDNA samples collected 1 hour after surgery. Patients with detected ctDNA in blood collected 1 hour after surgery compared to patients without detected ctDNA had higher likelihood of melanoma recurrence (P < 0.001) and shorter median disease-free survival (P = 0.001) and overall survival (P = 0.003). CONCLUSIONS: Ultrasensitive ddPCR can detect ctDNA in pre- and post-surgical blood samples from patients with resectable melanoma. Detection of ctDNA in post-surgical samples is associated with inferior treatment outcomes.
650    12
$a cirkulující nádorová DNA $x genetika $7 D000074141
650    _2
$a lidé $7 D006801
650    12
$a melanom $x genetika $7 D008545
650    12
$a mutace $7 D009154
650    _2
$a polymerázová řetězová reakce $7 D016133
650    12
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Polivka, J $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Department of Neurology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Huang, H J $u Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
700    1_
$a Treskova, I $u Department of Plastic Surgery, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Pivovarcikova, K $u Department of Pathology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Fikrle, T $u Department of Dermatovenerology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Woznica, Vlastimil $u Department of Plastic Surgery, University Hospital Pilsen, Pilsen, Czech Republic $7 xx0283194
700    1_
$a Dustin, D J $u Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
700    1_
$a Call, S G $u Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
700    1_
$a Meric-Bernstam, F $u Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
700    1_
$a Pesta, M $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Janku, F $u Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: fjanku@me.com
773    0_
$w MED00196632 $t ESMO open $x 2059-7029 $g Roč. 7, č. 1 (2022), s. 100357
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34942440 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20230310090104 $b ABA008
999    __
$a ok $b bmc $g 1788960 $s 1162332
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 7 $c 1 $d 100357 $e 20211220 $i 2059-7029 $m ESMO open $n ESMO Open $x MED00196632
GRA    __
$a P30 CA016672 $p NCI NIH HHS $2 United States
GRA    __
$a UL1 TR000371 $p NCATS NIH HHS $2 United States
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace